NCT03882801View on ClinicalTrials.gov

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

October 22, 2019

Study Completion Date

October 22, 2019

Conditions
Obstructive Sleep Apnea (OSA)
Interventions
DRUG

Gefapixant

In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.

DRUG

Placebo

In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.

Trial Locations (5)

9000

Universitair Ziekenhuis Gent ( Site 0012), Ghent

10019

Clinilabs, Inc. ( Site 0005), New York

30342

Neurotrials Research, Inc. ( Site 0001), Atlanta

33009

MD Clinical ( Site 0004), Hallandale

33024

Research Centers of America, LLC ( Site 0002), Hollywood

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03882801 - Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) | Biotech Hunter | Biotech Hunter